VEGF-A levels in serum are increased both in prostate cancer and benign prostatic hyperplasia patients, as compared to healthy individuals, but as individual serum levels have a considerable variance, VEGF-A is not a good predictor for disease progression itself [101]. This evidence concerns the gene VEGFA and benign prostatic hyperplasia.